Funding from Target ALS


We’re thrilled to announce the funding of a collaborative Target ALS Foundation Award of $1,000,000. The collaborative grant aims to find biomarkers for ALS and is with Jenna Gregory (Aberdeen University), Neil Shneider (Columbia University), and Gian Gaetano Tartaglia (Italian Institute of Technology, Genoa).


Comments

Post a Comment

Popular posts from this blog

Synuclein meeting 2025 in Cambridge

Image
  Last week, some members of the ESMB group attended the Synuclein meeting 2025 to hear about current and future approaches to target synulceinopathies. This event offered a very varied programme, with talks ranging from clinical and pre-clinical studies in the field of Parkinson’s disease and Multiple System Atrophy all the way to super-resolution imaging of aSynuclein aggregates. It was an amazing experience to get to hear from groups that have changed this field over the years and also to see all the new projects being set up to study these diseases onset and progression, therapies and diagnosis. It felt like going back to the origins of the group, where it all started! Finally, Gala dinner/party at King’s College Hall was definitely a highlight of the programme.
Read more

Abigail at Target ALS meeting in Boston

Image
Our post-doc Abigail attended the  annual Target ALS meeting in Boston last week along with the rest of our consortium members, including Gian Tartaglia, Jenna Gregory, Fergal Waldron, and Neil Shneider. Abigail was invited to present our group’s work on detecting TDP-43 in biological fluids using our TDP-43 aptamer ( Zacco et al., 2022 ) and super-resolution microscopy. There was also a sneak-peek of some of our work using the FUS aptamers, some of which is now in a pre-print ( Zacco et al., 2025 )! It's always great to hear about progress made in this field, many thanks to the organisers for hosting and to all our fellow consortium members who did a great job presenting our work. 
Read more

A new tool to detect and diagnose disease from blood samples

Image
We have developed an innovative method to detect small biological particles in blood samples, opening up new possibilities for earlier and more accurate disease diagnosis.  The technique, which we refer to as VISTA (Vesicle Imaging by Single-molecule TCCD Analysis), allows scientists to characterise tiny particles called extracellular vesicles (EVs), which are released by cells into the blood.  “This new tool is of huge potential, offering an easy way to obtain information from patient blood samples, without the need for invasive biopsies.” - Noelia. EVs carry molecular information of their cells of origin and are increasingly recognised as potential biomarkers for diseases such as cancer, Parkinson’s disease, and infections. However, because EVs are highly variable, and similar in size to other particles in the blood, they have been difficult to study using traditional methods. This new approach combines fluorescent labelling (to make EVs glow), microfluidics (a system that m...
Read more